Pomerantz Law Firm Files Class Action Against 3D Systems Over Securities Violations

Class Action Filed Against 3D Systems Corporation

On July 22, 2025, Pomerantz LLP announced the filing of a class action lawsuit against 3D Systems Corporation, listed under the stock symbol DDD. The lawsuit is registered in the United States District Court for the District of Delaware and seeks to represent all individuals and entities who acquired 3D Systems securities from August 13, 2024, to May 12, 2025. This legal action aims to recoup damages linked to the company's alleged breaches of federal securities laws.

Background of the Lawsuit

The class action alleges that during the specified Class Period, the defendants, which include key officers of the company, made significantly misleading statements regarding the company's operations and compliance with federal regulations. These statements reportedly understated the ramifications of reduced customer spending, overstated the resilience of the company's business, and failed to disclose that new milestone criteria in the company's partnership with United Therapeutics could adversely affect revenues from its Regenerative Medicine Program.

Investors who purchased securities of 3D Systems during this period have a deadline of August 12, 2025, to request to be appointed as Lead Plaintiff. Further details can be accessed through Pomerantz Law Firm’s website, where they provide a copy of the complaint and further instructions on participation in the lawsuit.

3D Systems Corporation Overview

3D Systems operates globally, providing advanced 3D printing and digital manufacturing solutions across various industries, including healthcare. Their Healthcare Solutions segment features innovations such as dental devices and personalized health services, reflecting the growing role of 3D printing in medical applications. Notably, their Regenerative Medicine Program aims to leverage additive manufacturing for organ transplants—a significant stride in medical technology.

Since 2018, 3D Systems has been collaborating with United Therapeutics Corporation to explore the potential of 3D printing lungs for patients suffering from severe lung diseases. The initiative emphasizes the company’s strategic focus on improving human health through innovative manufacturing techniques. Terms of this partnership necessitate meeting specific milestone criteria, which have been updated recently to reflect the evolving methodologies in testing.

Despite a notable decline in sales attributed to lower customer demand across the 3D printing sector, 3D Systems has continued to project optimism about its business future, boasting a robust product pipeline and an intention to increase gross margin and reduce operational costs. The company recently issued guidance for 2025, forecasting flat to mild growth despite a challenging marketplace.

Financial Performance and Market Reaction

However, the company has faced substantial challenges. For instance, in March 2025, 3D Systems reported its financial results for Q4 and the full-year 2024, including a non-GAAP earnings-per-share of -$0.19 and a drop in sales revenue. These figures not only fell below market expectations but also showcased the negative impact of broader economic pressures on their business model.

In the subsequent press release, the company acknowledged a revenue drop due to a revision in revenue recognition associated with the Regenerative Medicine Program, which led to a significant stock price drop following the announcement. Following its Q1 2025 earnings release, announcing a net loss and withdrawing its full-year 2025 outlook, the stock further declined by over 26%.

Market analysts have responded skeptically, questioning the viability of the company's trajectory towards profitability, particularly citing decreased revenues and ongoing investor hesitance in the 3D printing sector.

Conclusion and Legal Implications

As Pomerantz LLP pursues this class action, the outcomes may reflect broader implications not only for 3D Systems but the 3D printing industry's trust with its investors. Pomerantz is recognized for its expertise in securities class actions and has fought for victims of corporate fraud for over 85 years, seeking justice and accountability in the financial markets. Investors affected during the specific period are encouraged to engage with their legal firm to consider potential claims for recovery.